Following in the footsteps of upsized initial public offerings (IPOs) from PTC Therapeutics Inc. and Bluebird Bio, Plymouth, Mich.-based Esperion Therapeutics Inc. priced an IPO to raise $70 million – $80.5 million if underwriters exercise overallotments in full – to support midstage testing of its lead compound, ETC-1002, as an alternative to statin therapy in lowering LDL-cholesterol (LDL-C). Read More
LONDON – Heptares Ltd. has raised $21 million in a Series B funding co-led by the Stanley Family Foundation, one of the leading foundations investing in neuroscience diseases. Read More
When SEC Chairwoman Mary Jo White testified before a Senate Appropriations subcommittee this week, it wasn't to make excuses for missed deadlines under the Jumpstart Our Business Startups (JOBS) Act or promise when those long overdue rules would be released. Read More
Complix NV raised €12 million (US$15.6 million) in a Series B round to fund development of small-protein therapeutics based on its alphabody scaffold platform. Read More
• Chimerix Inc., of Durham, N.C., said it will be included in the Russell 2000, Russell 3000 and Russell Global Indexes at the close of market on June 28. Read More
• Labrys Biologics Inc., of San Mateo, Calif., disclosed data from three late-breaking poster presentations demonstrating the pharmacokinetics and safety profile of LBR-101 (formerly RN-307) observed in multiple Phase I trials. Read More
